WO2009148229A3 - Peptide immunogène et composition contenant le peptide destinée à prévenir ou à traiter des maladies liées au vph - Google Patents

Peptide immunogène et composition contenant le peptide destinée à prévenir ou à traiter des maladies liées au vph Download PDF

Info

Publication number
WO2009148229A3
WO2009148229A3 PCT/KR2009/002713 KR2009002713W WO2009148229A3 WO 2009148229 A3 WO2009148229 A3 WO 2009148229A3 KR 2009002713 W KR2009002713 W KR 2009002713W WO 2009148229 A3 WO2009148229 A3 WO 2009148229A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
preventing
composition containing
related diseases
treating hpv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/002713
Other languages
English (en)
Korean (ko)
Other versions
WO2009148229A2 (fr
Inventor
이경률
임종백
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocore Co Ltd
Original Assignee
Biocore Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocore Co Ltd filed Critical Biocore Co Ltd
Publication of WO2009148229A2 publication Critical patent/WO2009148229A2/fr
Publication of WO2009148229A3 publication Critical patent/WO2009148229A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un peptide immunogène et une composition contenant le peptide destinée à prévenir ou à traiter des maladies liées au VPH, et plus particulièrement, un peptide immunogène E7 dérivé d'une protéine E7 de type 16 du VPH, ainsi qu'une composition contenant le peptide destinée à prévenir ou à traiter des maladies liées au VPH.
PCT/KR2009/002713 2008-06-02 2009-05-22 Peptide immunogène et composition contenant le peptide destinée à prévenir ou à traiter des maladies liées au vph Ceased WO2009148229A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0051833 2008-06-02
KR1020080051833A KR20090125629A (ko) 2008-06-02 2008-06-02 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
WO2009148229A2 WO2009148229A2 (fr) 2009-12-10
WO2009148229A3 true WO2009148229A3 (fr) 2010-03-04

Family

ID=41398643

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/002713 Ceased WO2009148229A2 (fr) 2008-06-02 2009-05-22 Peptide immunogène et composition contenant le peptide destinée à prévenir ou à traiter des maladies liées au vph

Country Status (2)

Country Link
KR (1) KR20090125629A (fr)
WO (1) WO2009148229A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190020098A (ko) 2016-06-20 2019-02-27 아이에스에이 파마슈티컬즈 비.브이. 펩타이드 백신의 제형
CN110139873A (zh) 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 Hpv特异性结合分子
AU2017355564B2 (en) * 2016-11-07 2022-04-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of agonist epitopes of the human papillomavirus
BR112020006643A2 (pt) 2017-10-03 2020-09-24 Juno Therapeutics Inc moléculas de ligação específica ao hpv
AU2019249209A1 (en) 2018-04-05 2020-10-15 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
EP4701650A2 (fr) 2023-04-26 2026-03-04 Isabella Pharma B.V. Procédés de traitement du cancer par administration de compositions immunogènes et d'un inhibiteur de pd-1

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060079453A1 (en) * 2002-10-03 2006-04-13 John Sidney Hla binding peptides and their uses
WO2009120022A2 (fr) * 2008-03-28 2009-10-01 바이오코아 주식회사 Immunopeptide, composition pour la prophylaxie ou le traitement d'états pathologiques médicaux liés au hpv comprenant l'immunopeptide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060079453A1 (en) * 2002-10-03 2006-04-13 John Sidney Hla binding peptides and their uses
WO2009120022A2 (fr) * 2008-03-28 2009-10-01 바이오코아 주식회사 Immunopeptide, composition pour la prophylaxie ou le traitement d'états pathologiques médicaux liés au hpv comprenant l'immunopeptide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SARAH A. COMERFORD ET AL.: "Identification ofT- and B-Cell Epitopes of the E7 Protein of Human Papillomavirus Type 16", JOURNAL OF VIROLOGY, vol. 65, no. 9, September 1991 (1991-09-01), pages 4681 - 4690 *

Also Published As

Publication number Publication date
WO2009148229A2 (fr) 2009-12-10
KR20090125629A (ko) 2009-12-07

Similar Documents

Publication Publication Date Title
WO2009059325A8 (fr) Compositions de peptide hpv multitype et procédés de traitement ou de prévention d'une infection par papillomavirus humain
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
WO2009137721A3 (fr) Peptides de ciblage lysosomial et leurs utilisations
EP2455462A3 (fr) Variantes de lipase pour utilisation pharmaceutique
WO2006036916A3 (fr) Modulation d'arni d'apob et utilisations correspondantes
EP2428222A3 (fr) Combinaisons de peptide de vaccin contre l'allergie aux chats
SG10201407640PA (en) Hepatitis b virus specific antibody and uses thereof
WO2009147248A3 (fr) Séquences d'acides aminés dirigées contre des protéines d'enveloppe d'un virus, et polypeptides comprenant ces séquences destinés au traitement de maladies virales
WO2008127364A3 (fr) Composés antiviraux et utilisation de ceux-ci
WO2008028117A3 (fr) Miméticorps glp-2, polypeptides, compositions, procédés et utilisations
WO2009148229A3 (fr) Peptide immunogène et composition contenant le peptide destinée à prévenir ou à traiter des maladies liées au vph
WO2009002159A3 (fr) Vaccin intradermique contenant un peptide de pvh
WO2009004593A3 (fr) Procédés de préparation d'épinéphrine
WO2011157447A3 (fr) Parvovirus modifié présentant une plus grande efficacité antitumorale
WO2009148230A3 (fr) Peptide immunogène et composition contenant le peptide destinée à prévenir ou à traiter des maladies liées au vph
IL210538A0 (en) Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunuity
WO2011098778A8 (fr) Peptides pour vaccins contre l'allergie au bouleau
WO2007103584A3 (fr) Polyamides pour le traitement du virus du papillome humain
WO2010098583A2 (fr) Nouveau procédé de préparation de composés de statine ou des sels de ceux-ci, et composés intermédiaires utilisés dans ce procédé
WO2010057242A3 (fr) Vaccin
WO2009120022A3 (fr) Immunopeptide, composition pour la prophylaxie ou le traitement d'états pathologiques médicaux liés au hpv comprenant l'immunopeptide
WO2008033556A3 (fr) Traitement de protéines sous haute pression permettant de réduire leur immunogénicité
WO2007014077A3 (fr) Modulation de l'arni du gene rho-a et utilisations de celle-ci
WO2009103813A3 (fr) Compositions fongicides contenant du 3'-bromo-2,3,4,6'-tétraméthoxy-2'-6-diméthylbenzophénone
WO2009158238A3 (fr) Analogues de facteur de croissance de fibroblaste (fgf) et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09758482

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09758482

Country of ref document: EP

Kind code of ref document: A2